Sarah Campill

Navigating uncertainty: ethical considerations in communicating fluid biomarker based screening results and stratification-informed disease prognosis in pre-dementia stages of Alzheimer’s disease - A scoping review

Sarah Campill, Anne van Nifterick, Frederika Malichova

This scoping review, conducted within the FIGARO (Finding Alzheimer’s disease pROgression markers by cerebrospinal fluid proteomics) consortium, will map the literature on ethical and societal considerations surrounding the communication of fluid biomarker screening results, biomarker-based stratification, and disease prognosis in the pre-dementia …

National and international models of involving people with lived experience in dementia policy, advocacy and research

Ellen Snowball, Robin Casey, Karen Myers Barnett, Sarah Campill et autres

Globally, there is growing recognition of the need to advance approaches to involve people with lived experience of dementia as collaborators in policy, advocacy and research activities. Involvement is viewed as a right by dementia advocates and others, and some organizations have …

ca, us, lu, gb, ie (code pays fourni par la source)

Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study

Anna‐Katharine Brem, Zunera Khan, Jonas Radermacher, Kostas Georgiadis et autres

BACKGROUND: Recent developments in physiological, imaging and digital biomarkers combined with the approval of new disease-modifying drugs against Alzheimer's disease (AD) and diagnostic blood tests provide an opportunity to shift the first diagnostic steps to the home-setting. While these novel biomarkers enable …

au, de, gb, gr, no, us, es, dk, fr, lu, be, ch, at (code pays fourni par la source)

Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study

Anna‐Katharine Brem, Zunera Khan, Jonas Radermacher, Kostas Georgiadis et autres

Background: Recent developments in physiological, imaging and digital biomarkers combined with the approval of new disease-modifying drugs against Alzheimer’s disease (AD) and diagnostic blood tests provide an opportunity to shift the first diagnostic steps to the home-setting. While these novel biomarkers enable …

Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study.

Anna‐Katharine Brem, Zunera Khan, Jonas Radermacher, Kostas Georgiadis et autres

Background Recent developments in physiological, imaging and digital biomarkers combined with the approval of new disease-modifying drugs against Alzheimer's disease (AD) and diagnostic blood tests provide an opportunity to shift the first diagnostic steps to the home-setting. While these novel biomarkers enable …

gb (code pays fourni par la source)

“This also matters to me”: what does adherence to dementia risk reduction interventions mean to members of the public?

Ana Maria Diaz-Ponce, Sarah Campill, Mariagnese Barbera, Cindy Birck et autres

Growing evidence highlights the potential of multidomain lifestyle-based interventions to reduce the risk of cognitive decline among older adults at higher risk of cognitive impairment. Within these complex and often demanding interventions, adherence has emerged as a key factor influencing both outcomes …

lu, fi, gb, es, us, se, nl, de (code pays fourni par la source)

Informed Choices and Early Dementia Risk Disclosure in Home‐Based Assessments in the PREDICTOM Study: A Public Involvement Approach

Sarah Campill, Dianne Gove, Ana Diaz, Anna‐Katharine Brem et autres

BACKGROUND: The rapid progress in detecting dementia risk through emerging digital biomarkers and biofluid markers, alongside the development of disease modifying treatments (DMTs), underscores the importance of this evolving field. The PREDICTOM study leverages technological advances to develop an AI-driven platform for …

lu, ch, gb, no, au (code pays fourni par la source)

Prediction of Alzheimer's disease using an AI driven screening platform: interim results on feasibility, usability and acceptability of home‐based assessments in the PREDICTOM study

Anna‐Katharine Brem, Zunera Khan, Ellie Pickering, Martha Therese Gjestsen et autres

BACKGROUND: Early prediction of Alzheimer's disease (AD) is a critical healthcare challenge. The PREDICTOM study leverages technological advances in neurophysiological and digital biomarkers to develop an AI-driven platform enabling home-based early diagnostic assessment. Here, we assess the feasibility, usability, and acceptance of …

gb, no, de, us, at, dk, lu, gr (code pays fourni par la source)

Prediction of Alzheimer's disease using an AI driven screening platform: interim results of the PREDICTOM study

Anna‐Katharine Brem, Zunera Khan, Ellie Pickering, Jonas Botz et autres

BACKGROUND: Early prediction of Alzheimer's disease (AD) is an urgent health challenge. The aim of PREDICTOM is to develop and test the accuracy of an artificial intelligence (AI) driven screening platform for the prediction and early detection of AD and to extend …

ch, gb, de, us, at, dk, lu, no, fr, be, es, gr (code pays fourni par la source)

Informed Choices and Early Dementia Risk Disclosure in Home‐Based Assessments in the PREDICTOM Study: A Public Involvement Approach

Sarah Campill, Dianne Gove, Ana Diaz, Anna‐Katharine Brem et autres

Background The rapid progress in detecting dementia risk through emerging digital biomarkers and biofluid markers, alongside the development of disease modifying treatments (DMTs), underscores the importance of this evolving field. The PREDICTOM study leverages technological advances to develop an AI-driven platform for …

gb (code pays fourni par la source)

Prediction of Alzheimer's disease using an AI driven screening platform: interim results of the PREDICTOM study

Anna Katharine Brem, Zunera Khan, Ellie Pickering, Jonas Botz et autres

BACKGROUND: Early prediction of Alzheimer's disease (AD) is an urgent health challenge. The aim of PREDICTOM is to develop and test the accuracy of an artificial intelligence (AI) driven screening platform for the prediction and early detection of AD and to extend …

Everything Is Bound to Transform: On Knowledge’s Flow

Sarah Campill